02/01/12 - Sophia-Antipolis, France

MEDIAN signe un contrat majeur avec Sanofi

MEDIAN Technologies signe un contrat majeur avec le laboratoire SANOFI pour l’interprétation et la gestion des images dans une nouvelle étude de phase II sur le cancer du poumon à petites cellules.

 
More info >  (413.2 Kb, PDF File)

02/01/12 - Sophia-Antipolis, France

MEDIAN has signed a landmark contract with Sanofi

MEDIAN Technologies has signed a landmark contract with the top pharmaceutical company SANOFI for medical image interpretation and management in a new phase II study on small cells lung cancer.

 
More info >  (408.8 Kb, PDF File)
 

Clinical Routine

LMS addresses lung cancer and all cancers with potential lung and liver metastases: breast, colorectal, prostate, bronchial, head-and-neck, renal, eye, stomach, pancreas, bone sarcomas, choriocarcinomas, melanomas, testicular teratomas, thyroid carcinomas.

> Diagnosis
> Staging
> Assessment of Response to Therapy
> Surveillance

 

Diagnosis

LMS facilitates the diagnosis of lung cancer by providing Computer Aided Detection (CAD) of pulmonary lesions and automatic follow-up of indeterminate lung nodule.

Computer Aided Detection

LMS automatically highlights the spherical structures present in the lungs and increases the radiologists’ detection sensitivity.

Automatic Follow-up of Indeterminate Lung Nodule

LMS automatically calculates the volume growth and doubling time of indeterminate lung nodules in repeat CT scans.

 

Staging

CAD lung nodulesCancer staging is based on the exhaustive search of every secondary disease location. It implies identifying and reporting all metastases and especially lung metastases.

LMS-Lung has a built-in Computer Aided Detection algorithm to facilitate the detection of all lung metastases including the small ones (< 4mm) which are important to detect in cases such as testicular cancers or sarcomas.

 

 

Assessment of Response to Therapy

LMS was designed to provide quantitative assessment of response to therapy. Whether to perform the initial evaluation or the follow-up of a cancer patient, its automatic quantification tools are of great value to the clinicians.

Initial Evaluation

LMS facilitates the initial evaluation by providing:

  • Easy marking of measurable and non-measurable lesions
  • Automatic measurement of lung and liver lesion longest axial diameter and volume
  • Manual measurement of lymph nodes or other lesions identified on CT images covering the lungs and/or liver area.
  • Easy reporting of target and non-target lesions

Follow-up

LMS automates lesion follow-up and reporting in the following ways:

  • Automatic image synchronization and lesion pairing in repeat CT scans
  • Automatic calculation of all measurable lesion growth
  • Built-in Computer Aided Detection algorithm to facilitate the detection of new lung metastases
  • Automatic generation of reports according to RECIST criteria

Follow-up

 

Surveillance

Patients cured from cancer must still be followed in order to make sure that there is no recurrence.

LMS automates the follow-up of residual mass by synchronizing the images in repeat CT scans. Additionally, the built-in Computer Aided Detection algorithm facilitates the detection of new lung lesions.